Reduces inflammation of the bronchial cells so used to treat inflammation of the bronchial cells, and in the maintenance treatment of asthma Permanent In severe cases worsening repeated. This medicine is used in asthma every day, even if Haralamarb better; and does not reduce the dose or stop this medication unless otherwise telling your doctor.
UsesUsing oral inhalation to address the maintenance of acute asthma permanent. And maintenance treatment in severe cases worsening repeated.Pregnant women should be discouraged from continuing use Kortkowstroyd by inhalation.Used by nasal sprays of runny nose processing.ContraindicationsSensitivity to Pklomithazon, or materials used in the compound.Children less than 5 years.PrecautionsPregnancy: safe for use when used by inhalation.Breastfeeding: used with caution.Used
with caution when there is a defect in the thyroid gland, kidney
failure, liver failure, heart disease, diabetes, glaucoma, there is a
risk of osteoporosis, a lack of adrenal, psychological diseases such as
landing the respiratory system, and there is the risk of epilepsy, or
diseases of the digestive system, such as ulcer.Side effectsCommon
symptoms: hoarseness, cough, the growth of Candida albicans in the
mouth, pharynx (when use Kortkowstroyd by inhalation by a particular
device, you should rinse your mouth with water, gargle and spit
externally).Rare: allergic reaction, including shrinking bronchitis, rashes, swelling and redness.Adopt
a comprehensive anti effects on the overall amount of absorption, which
is affected by the dose, and the duration of treatment and the proper
use of system.Headache, falling Aljhazaltnevsa, dizziness, confusion.Hypoadrenia: risk increases in the high dose, especially in older patients. .Bone density loss: clinical outcomes that relate to the risk of osteoporosis and fracture is still unknown.Glaucoma: the risk may be increased.Weakness
in growth: inhalation Kortcostraad may reduce the speed of growth
mainly in the first year of treatment; impact on growth of other organs
(eg: brain, lung) is not clearly defined; uncontrolled asthma may cause
delay in growth as well.Drug InteractionsAlkorteqostroad
can increase the potassium deficiency, which may occur during the use
of diuretics that do not provide potassium, and amphotericin - B -.Use Alkorteqostroad in the same time with Filorrukwynelon (antibiotic) increases the risk of tendonitis.Alkorteqostroad can minimize the impact of diabetes medications sugar-lowering.Doses and methods of useAdults: by inhalation, 40-80 Mkrogm twice a day; a maximum 320 Mkrogm dose twice a day in severe asthma permanent.Children> 5 years: 40 Mkrogm twice a day; or 80 Mkrogm twice a day.In
most asthma daily therapeutic dose 80-250 Mkrogm; dose> 500 Mkrogm
day Used in severe asthma and requires specialist supervision.- The primary dose is likely to be effective, then turn to a low dose if required the need to keep control of asthma.- Reducing the dose every 3 months, approximately reduced by 25% if the completion of asthma control.- Pregnant women should be discouraged from continuing use Kortkowstroyd by inhalation.-
Use this medication every day, even if I felt better; do not reduce the
dose or stop this medicine unless your doctor tells you.Dosage formsMy
Illaúb onto a puffer for oral inhalation in the form of dual-propionate
(40 micrograms / inhalation), (50 micrograms / inhalation), (80
micrograms / inhalation). (100 micrograms / inhalation), (250 micrograms
/ inhalation).Hanging inside the nasal spray: 42 micrograms / 1 Stnchaqh.Chemical formula MolecularDual propionate Baklomettazon molecular formula: C28H37C1O7Relative molecular mass (g / mol)521StorageYou must save the medication away from light and moisture at room temperature below 25 degrees Celsius.
